Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5

Conditions

Glioblastoma 5Glioma 4Brain Neoplasms 4Recurrence 1

Interventions

pembrolizumab 1262Specimen Handling 924Magnetic Resonance Spectroscopy 829Carboplatin 821Cyclophosphamide 799Cisplatin 722Nivolumab 667Paclitaxel 627Radiotherapy 608Gemcitabine 570Biopsy 557Bevacizumab 478Dexamethasone 437fludarabine 407Docetaxel 377venetoclax 367Oxaliplatin 364Capecitabine 355Fluorouracil 355atezolizumab 350durvalumab 332Rituximab 329Drug Therapy 325Doxorubicin 316Radiosurgery 314Standard of Care 309Blood Specimen Collection 308Pemetrexed 304Ipilimumab 298Radiation 285

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Dianhydrogalactitol × 1 year × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT03050736 2025-09-04

Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression

Kintara Therapeutics, Inc.

Phase 2 Completed
29 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT03149575 2025-09-04

STAR-3

Kintara Therapeutics, Inc.

Phase 3 Terminated
2 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT01478178 2025-08-29

Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma

Kintara Therapeutics, Inc.

Phase 1/2 Completed
55 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT02717962 2025-08-29

Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting

Kintara Therapeutics, Inc.

Phase 2 Completed
118 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡